Recovery From Anesthesia After Robotic Assisted Radical Cystectomy

Phase 4

• Conditions: Anesthesiology Management
• Interventions: Drug: Sugammadex Injectable Product; Drug: Neostigmine, Atropine

• Registration Number: NCT03144453
• Lead Sponsor: Regina Elena Cancer Institute

Brief Summary

Robot-assisted radical cystectomy (RARC) requires specific surgical conditions: steep Trendelenburg position, prolonged pneumoperitoneum, effective neuromuscular block until the final stages of surgery. The aim of this study was to evaluate the quality of awakening in two groups of patients undergoing different combinations of curarization/reversal.

Detailed Description

Not available

Study Timeline

• Study Start: 2017-05-02
• Study First Submitted: 2017-05-03
• Study First Submitted QC: 2017-05-05
• Study First Posted: 2017-05-08
• Status Verified: 2019-01
• Last Update Submitted: 2019-01-25
• Last Update Posted: 2019-01-28
• Primary Completion: 2019-12
• Study Completion: 2019-12

Recruitment & Eligibility

• Status: UNKNOWN
• Sex: All
• Target Recruitment: 50

Inclusion Criteria

• ASA (american society of anesthesiologists) score ≤ III
• Patients underwent robotic assisted cystectomy

Exclusion Criteria

• Cerebrovascular disease
• BMI (body mass index) ≥ 30

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: PARALLEL

Arm && Interventions

Group	Intervention	Description
Sugammadex	Sugammadex Injectable Product	The patients received sugammadex as neuromuscular blockade reversal
Standard	Neostigmine, Atropine	The patients received neostigmine + atropine as neuromuscular blockade reversal

Primary Outcome Measures

Name	Time	Method
Time to discharge from recovery room	Up to 240 Minutes After recovery	Time between reversal administration and discharge from the recovery room

Trial Locations

Locations (2)

Ester Forastiere; 🇮🇹 Rome, RM, Italy

Regina Elena Cancer Institute; 🇮🇹 Rome, RM, Italy